Free Trial

Cerevel Therapeutics (CERE) Stock Forecast & Price Target

$43.37
-0.03 (-0.07%)
(As of 07/24/2024 ET)

Cerevel Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 9 Wall Street analysts who have issued ratings for Cerevel Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 9 analysts, 8 have given a hold rating, and 1 has given a buy rating for CERE.

Consensus Price Target

$42.67
-1.62% Downside
High Forecast$45.00
Average Forecast$42.67
Low Forecast$31.00

According to the 9 analysts' twelve-month price targets for Cerevel Therapeutics, the average price target is $42.67. The highest price target for CERE is $45.00, while the lowest price target for CERE is $31.00. The average price target represents a forecasted downside of -1.62% from the current price of $43.37.

TypeCurrent Forecast
7/26/23 to 7/25/24
1 Month Ago
6/26/23 to 6/25/24
3 Months Ago
4/27/23 to 4/26/24
1 Year Ago
7/26/22 to 7/26/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
8 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$42.67$42.67$41.40$34.80
Forecasted Upside-1.62% Downside15.16% Upside13.31% Upside27.89% Upside
Get Cerevel Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.

CERE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CERE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cerevel Therapeutics Stock vs. The Competition

TypeCerevel TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.11
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-1.62% Downside3,257.63% Upside10.62% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/16/2024Mizuho
2 of 5 stars
 Boost TargetNeutral ➝ Neutral$25.00 ➝ $45.00+5.71%
12/28/2023JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetNeutral ➝ Neutral$25.00 ➝ $45.00+6.38%
12/22/2023Jefferies Financial Group
2 of 5 stars
 Reiterated RatingBuy ➝ Hold$40.00 ➝ $45.00+8.72%
12/8/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$45.00+9.41%
12/7/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$41.00 ➝ $45.00+9.78%
12/7/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$38.00 ➝ $45.00+21.85%
12/7/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Neutral$33.00 ➝ $45.00+21.85%
11/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$42.00 ➝ $38.00+52.73%
8/3/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$36.00 ➝ $31.00+17.74%
5/4/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$30.00-6.02%
3/16/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$22.00-10.02%
11/1/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$40.00+43.06%
9/21/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$24.00 ➝ $28.00+1.71%
9/12/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:03 AM ET.

CERE Forecast - Frequently Asked Questions

What is Cerevel Therapeutics' forecast for 2024?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Cerevel Therapeutics is $42.67, with a high forecast of $45.00 and a low forecast of $31.00.

Should I buy or sell Cerevel Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares.

Does Cerevel Therapeutics's stock price have much upside?

According to analysts, Cerevel Therapeutics's stock has a predicted upside of 15.16% based on their 12-month stock forecasts.

Do Wall Street analysts like Cerevel Therapeutics more than its competitors?

Analysts like Cerevel Therapeutics less than other "medical" companies. The consensus rating for Cerevel Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CERE compares to other companies.


This page (NASDAQ:CERE) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners